Sobril is a brief-acting benzodiazepine. It will increase neuronal membrane permeability to Cl ions by binding to stereospecific benzodiazepine receptors around the postsynaptic GABA neuron w/inside the CNS (including the limbic technique, reticular formation) and improving the GABA inhibitory outcomes leading to hyperpolarisation and stabilisation